Lexeo Therapeutics (LXEO) PT Lowered to $9 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LXEO Hot Sheet
Price: $3.23 +3.86%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Leerink Partners analyst Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ: LXEO) to $9.00 (from $10.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Oppenheimer Downgrades Fidelity National Information Services (FIS) to Perform
- Northland on SolarEdge (SEDG): 'Storage remains a bright spot for the Company'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
